Previous 10 | Next 10 |
home / stock / tkphf / tkphf news
Summary Ascendis is a mid-cap commercial biotech based in Denmark. Currently, it trades around $6.7B market cap, and the company holds $900M cash. Skytrofa (TransCon hGh) is Ascendis' lead approved agent for pediatric growth hormone deficiency (GHD), where the commercial update was luke...
The following slide deck was published by Takeda Pharmaceutical Company Limited in conjunction with this event. For further details see: Takeda Pharmaceutical Company (TAK) Presents At 41st Annual Healthcare Conference - Slideshow
Summary Denali Therapeutics Inc. has major partnerships and an active set of programs. They are flush with cash. Denali Therapeutics needs to show us human patient data. I have been covering Denali Therapeutics Inc. ( DNLI ) for a few years now. Denali has three th...
Summary Qitan Technology, a Chengdu nanopore sequencing company, completed a $101 million Series C round to support its commercialized nanopore devices. Takeda was approved to launch Exkivity (mobocertinib) in China to treat NSCLC patients with epidermal growth factor receptor (EGFR) Ex...
Summary ADMA Biologics continues to outperform benchmarks, after offering investors a source of tactical alpha across the past 18 months. The market continues to reward its hypothesis in treating primary humoral immunodeficiency. Shares have extended the rally in 2023 and further up...
Summary "Dividend Aristocrats" is an S&P term for stocks that have raised their annual dividend every year for many years, 25 in the US or 10 internationally. As a strategy, investing in dividend aristocrats is backwards-looking, but does a decent job of screening companies with som...
Summary My portfolio, built specifically for my retirement ~20+ years from now gets a nice end-of-the-year Petrobras dividend to help ease market pain. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping creat...
Summary Karyopharm Therapeutics hasn't done a lot of impressive stuff in the last 6 months. It is trading at 52-week lows, but that may not be a good thing by itself. I will stay on the sidelines, because I am unable to see the value here. I covered Karyopharm Therapeu...
The following slide deck was published by Takeda Pharmaceutical Company Limited in conjunction with their 2022 Q2 earnings call. For further details see: Takeda Pharmaceutical Company Limited 2022 Q2 - Results - Earnings Call Presentation
Summary Strong top-line growth exhibited in FY22. Building regulatory and clinical momentum around its core offerings, with the bulk of the portfolio up double digits this year. Technicals, valuations equally as supportive for upside capture. Rate buy, FY23 price objective $32.4...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Co Ltd Company Name:
TKPHF Stock Symbol:
OTCMKTS Market:
Takeda Pharmaceutical Co Ltd Website:
Usinas Siderurgicas De Minas Gerais S.A. ADR (Representing Pref Share Cl A) (USNZY) is expected to report $0 for Q2 2024 CREATD INC. (CRTD) is expected to report for Q1 2024 Bluegreen Vacations Holding Corporation - Class B (BVHBB) is expected to report for Q1 2024 Senstar Technologie...
Verbund AG ADR (OEZVY) is expected to report for Q1 2024 Rent the Runway Inc. (RENT) is expected to report $-6.56 for Q1 2025 Johnson Matthey plc ADR (JMPLY) is expected to report for Q4 2024 RVL Pharmaceuticals plc (RVLPQ) is expected to report for Q1 2024 Ciena Corporation (CIEN...
JD.com Inc. (JD) is expected to report $0.56 for Q1 2024 Volkswagen AG (VLKAF) is expected to report for Q1 2024 CalAmp Corp. (CAMP) is expected to report for Q4 2024 Sonic Foundry Inc. (SOFO) is expected to report for Q2 2024 Moatable Inc ADR (R2RS:MU) is expected to report for Q...